GO Girls is a national charity, supported by our patron, Helen Lederer. We provide one of the UK's only online support groups for women with any gynaecological cancer run by medical professionals, raise awareness of these diseases and campaign for earlier diagnostics and improved treatments.

Go Girls

twitter

GO Girls, a national charity which supports women with all five gynaecological cancers, today welcomed the decision by the National Institute for Health and Care Excellence (NICE) to issue a final appraisal determination (FAD) recommending the use of JEMPERLI®▼ (dostarlimab) via the Cancer Drugs Fund (CDF). It provides a treatment option for patients with a common and aggressive form of advanced endometrial cancer (cancer of the womb lining).&nbsp; To date, beyond chemotherapy, there have been limited treatment options for women with advanced, recurrent endometrial cancer in England. Now patients whose cancer has a specific abnormality called MSI-H or MMR deficiency have the opportunity to access immunotherapy with dostarlimab. This is a step forward in improving outcomes for women with endometrial cancer by delivering tailored treatment.The prognosis for patients diagnosed with advanced/recurrent endometrial cancer is extremely poor and for those with advanced cancer, there are still relatively few treatment options that can improve their lives or prognosis. &nbsp;<blockquote>Hilary Maxwell, Chair of GO Girls said: “GO Girls was delighted to be part of the NICE process to advocate the importance of choice in advanced endometrial cancer. Endometrial cancer is the most commonly diagnosed gynaecological cancer in the UK, and the 7th most common cause of cancer death in the UK. This positive outcome is the beginning of wider progress in the treatment and care of people affected by this devastating cancer.”</blockquote>